Investment Thesis
Nurix is a pre-commercial biotech showing promising 54% revenue growth but facing unsustainable cash burn of $168.5M annually against only $67.7M in cash reserves. Losses are worsening significantly (up 36.6% YoY) despite revenue gains, indicating expenses are growing faster than commercialization can offset, creating an imminent capital crisis within 5 months at current burn rates.
Strengths
- Strong liquidity position with 6.34x current ratio and zero debt eliminates financial distress risk
- Revenue growing 54% YoY indicating successful early commercialization or partnership value
- Solid balance sheet with $402.6M equity and only $132.9M liabilities provides runway for operations
Risks
- Operating cash burn of $168.5M annualized against $67.7M cash creates critical runway crisis within 5 months requiring immediate capital raise
- Losses deteriorating despite revenue growth: net loss increased 36.6% YoY while revenue grew 54%, indicating expenses scaling faster than revenue
- Extreme negative margins (-1155% net, -1220% operating) demonstrate business is far from sustainability without massive revenue inflection
Key Metrics to Watch
- Quarterly revenue trajectory and commercial traction sustainability
- Monthly cash burn rate and path to cash flow breakeven
- Capital raise activity and dilution impact on equity
Financial Metrics
Revenue
15.3M
Net Income
-176.7M
EPS (Diluted)
$-1.60
Free Cash Flow
-171.5M
Total Assets
535.5M
Cash
67.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,220.7%
Net Margin
-1,155.3%
ROE
-43.9%
ROA
-33.0%
FCF Margin
-1,121.1%
Balance Sheet & Liquidity
Current Ratio
6.34x
Quick Ratio
6.34x
Debt/Equity
0.00x
Debt/Assets
24.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-08-04T06:09:09.162414 |
Data as of: 2026-05-31 |
Powered by Claude AI